{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:14:06Z","timestamp":1768788846916,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,7,4]],"date-time":"2015-07-04T00:00:00Z","timestamp":1435968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s10741-015-9496-5","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T08:37:29Z","timestamp":1435912649000},"page":"545-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms"],"prefix":"10.1007","volume":"20","author":[{"given":"Farzin","family":"Beygui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Tebbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Comin-Colet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Galinier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bramlage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Turgonyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Lins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda","family":"Imekraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinidad","family":"de Frutos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,4]]},"reference":[{"key":"9496_CR1","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787\u20131847","journal-title":"Eur Heart J"},{"key":"9496_CR2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251\u2013259","journal-title":"N Engl J Med"},{"key":"9496_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/heart.86.1.21","volume":"86","author":"TA McDonagh","year":"2001","unstructured":"McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ, Dargie HJ (2001) Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86:21\u201326","journal-title":"Heart"},{"key":"9496_CR4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1573403X11309020005","volume":"9","author":"K Guha","year":"2013","unstructured":"Guha K, McDonagh T (2013) Heart failure epidemiology: European perspective. Curr Cardiol Rev 9:123\u2013127","journal-title":"Curr Cardiol Rev"},{"key":"9496_CR5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/clc.20813","volume":"33","author":"M Volpe","year":"2010","unstructured":"Volpe M, Francia P, Tocci G, Rubattu S, Cangianiello S, Elena Rao MA, Trimarco B, Condorelli M (2010) Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study. Clin Cardiol 33:700\u2013707","journal-title":"Clin Cardiol"},{"key":"9496_CR6","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/euhj.2002.3282","volume":"23","author":"J Muntwyler","year":"2002","unstructured":"Muntwyler J, Abetel G, Gruner C, Follath F (2002) One-year mortality among unselected outpatients with heart failure. Eur Heart J 23:1861\u20131866","journal-title":"Eur Heart J"},{"key":"9496_CR7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"The SOLVD Investigators","year":"1992","unstructured":"The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685\u2013691","journal-title":"N Engl J Med"},{"key":"9496_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321","journal-title":"N Engl J Med"},{"key":"9496_CR9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(97)03033-X","volume":"350","author":"TA McDonagh","year":"1997","unstructured":"McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ (1997) Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 350:829\u2013833","journal-title":"Lancet"},{"key":"9496_CR10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0140-6736(01)05620-3","volume":"358","author":"M Davies","year":"2001","unstructured":"Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, Wosornu D, Lancashire RJ (2001) Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 358:439\u2013444","journal-title":"Lancet"},{"key":"9496_CR11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/euhj.1998.1239","volume":"20","author":"A Mosterd","year":"1999","unstructured":"Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, Grobbee DE (1999) Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 20:447\u2013455","journal-title":"Eur Heart J"},{"key":"9496_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2796.1997.129150000.x","volume":"241","author":"M Kupari","year":"1997","unstructured":"Kupari M, Lindroos M, Iivanainen AM, Heikkila J, Tilvis R (1997) Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Intern Med 241:387\u2013394","journal-title":"J Intern Med"},{"key":"9496_CR13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/hrt.2003.025270","volume":"93","author":"A Mosterd","year":"2007","unstructured":"Mosterd A, Hoes AW (2007) Clinical epidemiology of heart failure. Heart 93:1137\u20131146","journal-title":"Heart"},{"key":"9496_CR14","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/eurheartj\/ehm102","volume":"28","author":"FD Hobbs","year":"2007","unstructured":"Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R (2007) Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5\u00a0year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 28:1128\u20131134","journal-title":"Eur Heart J"},{"key":"9496_CR15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/eurjhf\/hfs136","volume":"14","author":"AK Gitt","year":"2012","unstructured":"Gitt AK, Halle M, Hanefeld M, Kellerer M, Marx N, Meier JJ, Schumm-Draeger PM, Bramlage P et al (2012) Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? Eur J Heart Fail 14:1389\u20131400","journal-title":"Eur J Heart Fail"},{"key":"9496_CR16","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","volume":"29","author":"K Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29:2388\u20132442","journal-title":"Eur Heart J"},{"key":"9496_CR17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00392-009-0747-0","volume":"98","author":"TD Smilde","year":"2009","unstructured":"Smilde TD, van Veldhuisen DJ, van den Berg MP (2009) Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure. Clin Res Cardiol 98:233\u2013239","journal-title":"Clin Res Cardiol"},{"key":"9496_CR18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329\u20131338","journal-title":"N Engl J Med"},{"key":"9496_CR19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","volume":"363","author":"AS Tang","year":"2010","unstructured":"Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G et al (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:2385\u20132395","journal-title":"N Engl J Med"},{"key":"9496_CR20","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","volume":"52","author":"C Linde","year":"2008","unstructured":"Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C (2008) Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 52:1834\u20131843","journal-title":"J Am Coll Cardiol"},{"key":"9496_CR21","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1401426","volume":"370","author":"I Goldenberg","year":"2014","unstructured":"Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, Daubert JP, Estes NA 3rd et al (2014) Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 370:1694\u20131701","journal-title":"N Engl J Med"},{"key":"9496_CR22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","volume":"12","author":"F Zannad","year":"2010","unstructured":"Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J et al (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 12:617\u2013622","journal-title":"Eur J Heart Fail"},{"key":"9496_CR23","doi-asserted-by":"crossref","unstructured":"Tebbe U, Tsch\u00f6pe C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, Strunz AM, Lins K et al (2014) Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol","DOI":"10.1007\/s00392-014-0678-2"},{"key":"9496_CR24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.recesp.2014.03.014","volume":"67","author":"M Anguita","year":"2014","unstructured":"Anguita M, Comin-Colet J, Formiga F, Almenar L, Crespo-Leiro M, Manzano L (2014) Current situation of management of systolic heart failure in Spain: VIDA-IC study results. Management of systolic heart failure in Spain: current situation (VIDA \u2013 IC study) [Tratamiento de la insuficiencia card\u00edaca con funci\u00f3n sist\u00f3lica deprimida en Espa\u00f1a: situaci\u00f3n actual en Espa\u00f1a. Resultados del estudio VIDA-IC]. Rev Esp Cardiol 67:769\u2013780","journal-title":"Rev Esp Cardiol"},{"key":"9496_CR25","unstructured":"Comin-Colet J et al (2015) Health-related quality of life in chronic heart failure and ventricular systolic dysfunction patients and its association with clinic and demographic factors in Spain: results from the multicentre study VIDA-IC. Rev Esp Cardiol (submitted)"},{"key":"9496_CR26","author":"M B\u00f6hm","year":"2014","unstructured":"B\u00f6hm M, Tsch\u00f6pe C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, Lins K, Strunz AM et al (2014) Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF Registry in patients with NYHA Class II symptoms and a reduced ejection fraction. Clin Cardiol. doi: 10.1002\/clc.22375","journal-title":"Clin Cardiol"},{"key":"9496_CR27","unstructured":"Galinier M, Beygui F, Vicaut E, Imekraz L (2015) Prevalence of patients with NYHA class II and left ventricular ejection fraction\u00a0\u2264\u00a030% among a chronic heart failure population in France: The PAROS study. Minerva Cardioangiol (submitted)"},{"key":"9496_CR28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/eurjhf\/hfr093","volume":"13","author":"JJ McMurray","year":"2011","unstructured":"McMurray JJ (2011) CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail 13:929\u2013936","journal-title":"Eur J Heart Fail"},{"key":"9496_CR29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCULATIONAHA.106.666016","volume":"116","author":"WS Colucci","year":"2007","unstructured":"Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI et al (2007) Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the Reversal of Ventricular Remodeling with Toprol-XL (REVERT) trial. Circulation 116:49\u201356","journal-title":"Circulation"},{"key":"9496_CR30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(97)80008-6","volume":"349","author":"Australia\/New Zealand Heart Failure Research Collaborative Group","year":"1997","unstructured":"Australia\/New Zealand Heart Failure Research Collaborative Group (1997) Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349:375\u2013380","journal-title":"Lancet"},{"key":"9496_CR31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.CIR.92.2.212","volume":"92","author":"Australia-New Zealand Heart Failure Research Collaborative Group","year":"1995","unstructured":"Australia-New Zealand Heart Failure Research Collaborative Group (1995) Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92:212\u2013218","journal-title":"Circulation"},{"key":"9496_CR32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"Digitalis Investigation Group","year":"1997","unstructured":"Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525\u2013533","journal-title":"N Engl J Med"},{"key":"9496_CR33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293\u2013302","journal-title":"N Engl J Med"},{"key":"9496_CR34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB et al (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303\u2013310","journal-title":"N Engl J Med"},{"key":"9496_CR35","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","volume":"374","author":"MA Konstam","year":"2009","unstructured":"Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W et al (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374:1840\u20131848","journal-title":"Lancet"},{"key":"9496_CR36","doi-asserted-by":"crossref","unstructured":"(2000) Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 101:378\u2013384","DOI":"10.1161\/01.CIR.101.4.378"},{"key":"9496_CR37","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G, Valsartan Heart Failure Trial I (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667\u20131675","journal-title":"N Engl J Med"},{"key":"9496_CR38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349\u20131355","journal-title":"N Engl J Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-015-9496-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-015-9496-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-015-9496-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T23:01:30Z","timestamp":1559257290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-015-9496-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,4]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["9496"],"URL":"https:\/\/doi.org\/10.1007\/s10741-015-9496-5","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,4]]}}}